natgillin/translations-raw huggingface dataset:
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Lojuxta's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Lojuxta večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Treatment should begin at a dose of 5 mg once per day, and if well tolerated may be steadily increased to a maximum dose of 60 mg per day. 
Zdravljenje je treba začeti z odmerkom 5 mg enkrat na dan in ga je mogoče postopoma povečevati do najvišjega odmerka 60 mg na dan, če ga bolnik dobro prenaša.
The most common side effects are problems with the gut, which may affect as many as 9 out of 10 people: diarrhoea and nausea (feeling sick) were each seen in around 7 out of 10 people, dyspepsia (heartburn) and vomiting were each seen in more than 3 out of 10 people, while pain, discomfort and bloating of the abdomen (belly), constipation and flatulence were each seen in at least 2 out of 10 people. 
Najpogostejši neželeni učinki so težave s prebavili, ki se lahko pojavijo pri 9 ljudeh od 10: drisko in navzejo (slabost) so opazili pri približno 7 osebah od 10, dispepsijo (zgago) in bruhanje so opazili pri več kot 3 osebah od 10, medtem ko so bolečino, neugodje in napihnjenost trebuha, zaprtje in flatulenco opazili pri vsaj 2 osebah od 10.
What measures are being taken to ensure the safe and effective use of Lojuxta? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Lojuxta?
The study will also provide data on pregnancies in women taking the medicine, and on healthcare professionals' compliance with the recommendations to screen and monitor patients before and during treatment. 
S študijo bodo pridobljeni tudi podatki o nosečnostih pri ženskah, ki so jemale zdravilo, in o tem, kako zdravstveni delavci upoštevajo priporočila za presejanje in spremljanje bolnikov pred in med zdravljenjem.
Lojuxta was not compared with any other treatment. 
Zdravila Lojuxta niso primerjali z nobenim drugim zdravljenjem.
Lojuxta has been authorised under ‘exceptional circumstances'. 
Zdravilo Lojuxta je pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
Patients taking certain other medicines may also need to take a reduced dose or take Lojuxta and their other medication at different times. 
Bolniki, ki jemljejo določena druga zdravila, bodo tudi morali jemati zmanjšan odmerek oziroma jemati zdravilo Lojuxta in njihova druga zdravila ob različnih časih.
It must also not be used by patients with moderately or severely reduced liver function or with unexplained, abnormal liver test results, or by patients with significant or long-term bowel problems. 
Prav tako ga ne smejo uporabljati bolniki z zmerno ali močno zmanjšanim delovanjem jeter, bolniki z nepojasnjenimi, nenormalnimi rezultati preiskav jetrnega delovanja in bolniki s pomembno ali kronično črevesno boleznijo.
A risk management plan has been developed to ensure that Lojuxta is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Lojuxta je bil pripravljen načrt za obvladovanje tveganja.
Treatment should be started and monitored by a doctor experienced in treating conditions involving high levels of fats in the blood. 
Zdravljenje mora uvesti in spremljati zdravnik z izkušnjami z zdravljenjem visokih ravni maščob v krvi.
The Committee also noted that Lojuxta had side effects in the gut in most patients, which caused some patients to stop treatment, and that it led to increased liver enzyme levels whose long-term consequences are not known. 
Odbor je opozoril tudi, da je imelo zdravilo Lojuxta pri večini bolnikov neželene učinke na prebavila, zaradi katerih so nekateri bolniki prekinili zdravljenje, in da je povzročilo povišane ravni jetrnih encimov, katerih dolgoročne posledice niso znane.
The benefits of Lojuxta in reducing blood cholesterol were assessed in a main study involving 29 patients with homozygous familial hypercholesterolaemia. 
Koristi zdravila Lojuxta pri zmanjševanju holesterola v krvi so bile ocenjene v glavni študiji, ki je vključevala 29 bolnikov s homozigotno družinsko hiperholesterolemijo.
It is used to treat adult patients with homozygous familial hypercholesterolaemia, an inherited disease causing high blood levels of cholesterol (a type of fat). 
Uporablja se za zdravljenje odraslih bolnikov s homozigotno družinsko hiperholesterolemijo, tj. dedno boleznijo, ki povzroča visoke ravni holesterola (vrste maščobe) v krvi.
Lojuxta must not be used in women who are pregnant. 
Zdravila Lojuxta ne smejo uporabljati nosečnice.
By blocking this protein, Lojuxta decreases the level of fats released into the blood, thereby helping to reduce the level of cholesterol in hypercholesterolaemia. 
Z zaviranjem tega proteina zdravilo Lojuxta zmanjšuje raven maščob, ki se sproščajo v kri, in na ta način pomaga zmanjševati raven holesterola pri hiperholesterolemiji.
Microsomal triglyceride transfer protein is involved in assembling fatty substances such as cholesterol and triglyceride into larger particles called lipoproteins, which are then released into the blood stream. 
Mikrosomalni protein za prenos trigliceridov je vključen v sestavljanje maščobnih snovi, kot so holesterol in trigliceridi, v večje dele, imenovane lipoproteini, ki se nato sprostijo v krvni obtok.
Other information about Lojuxta 
Druge informacije o zdravilu Lojuxta
Since Lojuxta has been approved under exceptional circumstances, the company that markets the medicine is carrying out a long-term study in patients taking Lojuxta to provide further data on its safety and effectiveness, including its side effects on the liver, stomach, gut, and cardiovascular system. 
Ker je zdravilo Lojuxta pridobilo dovoljenje za promet v izjemnih okoliščinah, bo družba, ki ga trži, opravila dolgoročno študijo pri bolnikih, ki ga jemljejo, s čimer bo zagotovila dodatne podatke o njegovi varnosti in učinkovitosti, vključno z njegovimi neželenimi učinki na jetra, želodec, črevo in srčno-žilni sistem.
Lojuxta must not be used together with over 40 mg per day of simvastatin (another medicine used to lower blood cholesterol levels) or with certain other medicines that affect the way lomitapide is broken down in the body. 
Zdravila Lojuxta se ne sme uporabljati skupaj z odmerki simvastatina (drugega zdravila za zniževanje ravni holesterola v krvi), ki presegajo 40 mg na dan, ali z določenimi drugimi zdravili, ki vplivajo na razgradnjo lomitapida v telesu.
What is Lojuxta and what is it used for? 
Kaj je zdravilo Lojuxta in za kaj se uporablja?
For more information about treatment with Lojuxta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Lojuxta preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Patients should avoid drinking grapefruit juice while taking Lojuxta. 
Bolniki se morajo v času jemanja zdravila Lojuxta izogibati pitju soka grenivke.
Lojuxta is a medicine that contains the active substance lomitapide. 
Lojuxta je zdravilo, ki vsebuje zdravilno učinkovino lomitapid.
The most serious side effect seen in some patients treated with Lojuxta is abnormally raised liver enzyme levels. 
Najresnejši neželeni učinek, ki se je pojavil pri nekaterih bolnikih, zdravljenih z zdravilom Lojuxta, so bile nenormalno povišane ravni jetrnih encimov.
This is because it has not been possible to obtain complete information about Lojuxta to date due to the rarity of the disease. 
Do tega je prišlo zato, ker zaradi redkosti bolezni ni bilo mogoče pridobiti vseh informacij o njem.
In addition, the company that markets Lojuxta will provide educational materials to all doctors expected to prescribe Lojuxta, containing information on how to select suitable patients as well as key safety information, including side effects, interactions with other medicines and use in women who could potentially have children. 
Poleg tega bo družba, ki trži zdravilo Lojuxta, za vse zdravnike, ki naj bi predpisovali to zdravilo, zagotovila izobraževalno gradivo, ki bo vsebovalo informacije o izbiri primernih bolnikov ter ključne varnostne informacije, vključno z neželenimi učinki, medsebojnim delovanjem z drugimi zdravili in uporabo pri ženskah, ki bi lahko bile noseče.
What benefits of Lojuxta have been shown in studies? 
Kakšne koristi je zdravilo Lojuxta izkazalo v študijah?
All patients were given Lojuxta together with other medicines for reducing the level of fats in the blood. 
Vsi bolniki so prejeli zdravilo Lojuxta skupaj z drugimi zdravili za zmanjševanje ravni maščob v krvi.
What are the risks associated with Lojuxta? 
Kakšna so tveganja, povezana z zdravilom Lojuxta?
The main measure of effectiveness was the change in the patients' blood levels of ‘low density lipoprotein' (LDL) cholesterol, commonly known as ‘bad cholesterol', after 26 weeks of treatment. 
Glavno merilo učinkovitosti je bila sprememba ravni „lipoproteinskega holesterola majhne gostote“ (LDL), ki ga pogosto imenujemo „slabi holesterol“, v krvi bolnikov po 26 tednih zdravljenja.
It is not intended to provide practical advice on how to use Lojuxta. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
For practical information about using Lojuxta, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Lojuxta naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
It is used together with a low fat diet and other medicines to reduce the level of fats in the blood. 
Uporablja se skupaj s prehrano z majhnim vnosom maščob in z drugimi zdravili za zmanjševanje ravni maščob v krvi.
Patients with moderately or severely reduced liver function must not take Lojuxta. 
Bolniki z zmerno ali močno zmanjšanim delovanjem jeter zdravila Lojuxta ne smejo jemati.
The CHMP considered that the medicine's effect in reducing LDL cholesterol levels was a benefit for patients with homozygous familial hypercholesterolaemia, who have an unmet medical need. 
Menil je, da je učinek zdravila pri zniževanju ravni LDL-holesterola koristen za bolnike s homozigotno družinsko hiperholesterolemijo in z neizpolnjeno potrebo po zdravilu.
Why is Lojuxta approved? 
Zakaj je bilo zdravilo Lojuxta odobreno?
Patients on kidney dialysis may need to take a reduced dose. 
Bolniki z boleznijo ledvic, ki prejemajo dializo, bodo morali jemati zmanjšan odmerek.
What information is still awaited for Lojuxta? 
Katere informacije o zdravilu Lojuxta še pričakujemo?
For the full list of side effects, see the package leaflet. 
Za celoten seznam neželenih učinkov glejte navodilo za uporabo.
The active substance in Lojuxta, lomitapide, blocks the action of a substance in the body called ‘microsomal triglyceride transfer protein', which is present in the cells of the liver and the gut. 
Zdravilna učinkovina zdravila Lojuxta, lomitapid, zavira delovanje snovi v telesu, imenovane „mikrosomalni protein za prenos trigliceridov“.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Lojuxta, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Lojuxta can only be obtained with a prescription. 
Izdaja zdravila Lojuxta je le na recept.
How is Lojuxta used? 
Kako se zdravilo Lojuxta uporablja?
How does Lojuxta work? 
Kako zdravilo Lojuxta deluje?
EU/2/09/102/001 GRIPOVAC 3 strains of inactivated 
EU/2/09/102/001 GRIPOVAC 3 seve inaktiviranega virusa Influenca
1GMNU = Geometric mean of neutralizing units induced in Guinea pigs after twice immunisation with 0.5 ml of this vaccine 
≥ 12.34 log2 GMNU1 1GMNU = Geometrijska sredina neutralizirajočih enot induciranih pri budrah po dvakratni imunizaciji z 0,5 ml tega cepiva
Influenza A virus/swine * 
A/prašiči*
* Strains of inactivated Influenza A virus/swine/ Bakum/IDT1769/2003 (H3N2) 
* Seve inaktiviranega virusa Influence A /prašiči/
What measures are being taken to ensure the safe and effective use of Natpar? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Natpar?
The usual recommended starting dose is 50 micrograms once a day. 
Priporočeni začetni odmerek je 50 mikrogramov enkrat dnevno.
The maximum daily dose is 100 micrograms. 
Največji dnevni odmerek je 100 mikrogramov.
It is not intended to provide practical advice on how to use Natpar. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Other information about Natpar 
Druge informacije o zdravilu Natpar
This is a summary of the European public assessment report (EPAR) for Natpar. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Natpar.
What is Natpar and what is it used for? 
Kaj je zdravilo Natpar in za kaj se uporablja?
As a result, patients have low levels of calcium which can cause problems in bones, muscles, heart, kidneys and other parts of the body. 
Bolniki imajo zato nizke ravni kalcija, kar lahko povzroči težave s kostmi, mišicami, srcem, ledvicami in drugimi deli telesa.
What benefits of Natpar have been shown in studies? 
Kakšne koristi je zdravilo Natpar izkazalo v študijah?
The summary of the opinion of the Committee for Orphan Medicinal Products for Natpar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Natpar je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
What are the risks associated with Natpar? 
Kakšna tveganja so povezana z zdravilom Natpar?
While the main study showed that Natpar helps control blood calcium levels while reducing the need for calcium and vitamin D supplements, the study was of short duration and there was no evidence of improvements in patients' quality of life or reductions in long-term problems such as kidney impairment. 
Čeprav je glavna študija pokazala, da zdravilo Natpar pomaga pri nadzoru ravni kalcija v krvi in zmanjšuje potrebo po nadomestkih kalcija in vitamina D, je bila študija kratkotrajna in ni bilo dokazov o izboljšanju kakovosti življenja bolnikov ali zmanjšanju dolgoročnih težav, kot je okvara ledvic.
Why is Natpar approved? 
Zakaj je bilo zdravilo Natpar odobreno?
The company that markets Natpar will set-up a registry and collect long-term data on patients treated with Natpar, including its effects on bones, kidneys and patients' quality of life. 
Družba, ki trži zdravilo Natpar, bo vzpostavila register in zbirala dolgoročne podatke o bolnikih, ki se zdravijo s tem zdravilom, vključno z njegovimi učinki na kosti, ledvice in kakovost življenja bolnikov.
The most common side effects with Natpar (which may affect more than 1 in 10 people) are too high or too low blood calcium levels, which can lead to headache, diarrhoea, vomiting, paraesthesia (unusual sensations like pins and needles), hypoaesthesia (reduced sense of touch) and high calcium levels in the urine. 
Najpogostejši neželeni učinki zdravila Natpar (ki se lahko pojavijo pri več kot 1 bolniku od 10) so previsoke ali prenizke ravni kalcija v krvi, kar lahko povzroči glavobol, diarejo, bruhanje, parestezijo (nenavadne občutke, kot je zbadanje), hipestezijo (zmanjšan občutek za dotik) in visoko raven kalcija v urinu.
Because of the limited data available, Natpar has been given ‘conditional approval'. 
Ker je na voljo omejena količina podatkov, je zdravilo Natpar pridobilo „pogojno dovoljenje za promet“.
For more information about treatment with Natpar, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Natpar preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The full EPAR for Natpar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Natpar je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Natpar have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Natpar upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Therefore, Natpar should only be used in patients who are not adequately controlled with standard treatments alone, who do not have other treatment options. 
Zdravilo Natpar naj se zato uporablja le pri bolnikih, pri katerih bolezni ni mogoče ustrezno nadzorovati samo s standardno terapijo, in bolnikih, ki nimajo drugih možnosti zdravljenja.
What information is still awaited for Natpar? 
Katere informacije o zdravilu Natpar še pričakujemo?
Because the number of patients with hypoparathyroidism is low, the disease is considered ‘rare', and Natpar was designated an ‘orphan medicine' (a medicine used in rare diseases) on 18 December 2013. 
Ker je bolnikov s hipoparatiroidizmom malo, velja ta bolezen za redko, zato je bilo zdravilo Natpar 18. decembra 2013 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Natpar is used as an add-on to treatment with calcium and vitamin D supplements when these treatments have not worked well enough. 
Zdravilo Natpar se uporablja kot dodatek k zdravljenju z dopolnili kalcija in vitamina D, kadar ta zdravila niso dovolj učinkovita.
In a main 24-week study involving 124 patients, 54.8% (46 out of 84) of the patients who received Natpar achieved and maintained acceptable blood calcium levels while reducing their doses of calcium and vitamin D supplements by at least 50%. 
V glavni 24-tedenski študiji, ki je vključevala 124 bolnikov, je 54,8 % bolnikov (46 bolnikov od 84), ki so prejemali zdravilo Natpar, doseglo in ohranilo ustrezne ravni kalcija ob vsaj 50-odstotnem zmanjšanju odmerkov dopolnil kalcija in vitamina D. Delež bolnikov, ki so prejemali placebo (zdravilo brez zdravilne učinkovine) in so dosegli enake rezultate, je bil 2,5 % (1 bolnik od 40).
How does Natpar work? 
Kako zdravilo Natpar deluje?
In patients with this condition, the parathyroid glands in the neck do not produce enough parathyroid hormone which controls the level of calcium in the blood. 
Pri bolnikih s to boleznijo paratiroidne žleze v vratu ne proizvajajo dovolj paratiroidnega hormona, ki uravnava raven kalcija v krvi.
Natpar must not be used in patients who are having or have had radiation therapy to the bones, who have bone cancer or cancer that has spread to the bones and are at increased risk of developing a bone cancer called osteosarcoma. 
Zdravilo Natpar se ne sme uporabljati pri bolnikih, ki se zdravijo ali so se zdravili z obsevanjem kosti, ki imajo kostnega raka ali raka, ki se je razširil na kosti, in ki jih ogroža tveganje za nastanek kostnega raka, imenovanega osteosarkom.
Natpar must also not be used in patients who have unexplained increases in the levels of an enzyme called bone alkaline phosphatase and those who have pseudohypoparathyroidism, a rare disease where the body does not respond adequately to the parathyroid hormone produced by the body. 
Zdravilo Natpar se prav tako ne sme uporabljati pri bolnikih, ki imajo nepojasnjene zvišane ravni encima, imenovanega kostna alkalna fosfataza, in tistih, ki imajo psevdohipoparatiroidizem, redko bolezen, pri kateri se telo neustrezno odziva na paratiroidni hormon, ki nastaja v telesu.
The active substance in Natpar, parathyroid hormone, is a copy of the natural hormone produced by the parathyroid glands. 
Zdravilna učinkovina v zdravilu Natpar, paratiroidni hormon, je kopija naravnega hormona, ki ga proizvajajo paratiroidne žleze.
Natpar has been shown to help control blood calcium levels in patients with hypoparathyroidism who are receiving calcium and vitamin D supplements. 
Zdravilo Natpar pomaga pri nadzoru ravni kalcija v krvi pri bolnikih s hipoparatiroidizmom, ki prejemajo dopolnila kalcija in vitamina D.
For practical information about using Natpar, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Natpar naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The medicine can only be obtained with a prescription and treatment should be supervised by a healthcare professional experienced in the management of patients with hypoparathyroidism. 
Predpisovanje in izdaja zdravila Natpar je le na recept, zdravljenje z njim pa mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s hipoparatiroidizmom.
Patients can inject Natpar themselves once they have been trained. 
Bolniki si lahko po ustreznem usposabljanju zdravilo Natpar injicirajo sami.
Since Natpar has been granted a conditional approval, the company that markets Natpar will conduct a further study to confirm the benefits and risks of the medicine and the appropriateness of the once-aday dosing schedule. 
Ker je zdravilo Natpar pridobilo pogojno dovoljenje za promet, bo družba, ki ga trži, izvedla dodatno raziskavo za potrditev tveganj in koristi zdravila ter primernosti odmerjanja enkrat dnevno.
How is Natpar used? 
Kako se zdravilo Natpar uporablja?
Natpar is available as a powder and a liquid that are mixed together to make a solution for injection. 
Zdravilo Natpar je na voljo v obliki praška in vehikla, ki se zmešata v raztopino za injiciranje.
Natpar is a hormone replacement medicine for treating adults with under-active parathyroid glands, a condition known as hypoparathyroidism. 
Zdravilo Natpar je hormonski nadomestek za zdravljenje odraslih s premalo delujočimi obščitničnimi (paratiroidnimi) žlezami, tj. boleznijo, znano kot hipoparatiroidizem.
It replaces the missing hormone in patients with hypoparathyroidism, thus helping to restore calcium levels. 
Pri bolnikih s hipoparatiroidizmom nadomešča manjkajoči hormon in tako pomaga uravnavati raven kalcija.
For the full list of all side effects reported with Natpar, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Natpar, glejte navodilo za uporabo.
Natpar replaces the missing parathyroid hormone in patients with hypoparathyroidism. 
Zdravilo Natpar nadomešča pomanjkanje paratiroidnega hormona pri bolnikih s hipoparatiroidizmom.
and calcium supplements, is then adjusted on the basis of the patient's blood calcium levels. 
Odmerek zdravila Natpar in bolnikov odmerek dopolnil vitamina D in kalcija se nato prilagajo glede na raven kalcija v bolnikovi krvi.
Regarding safety, the risk of calcium levels becoming too high or too low is considered important and further data are needed to better understand the consequences of wide fluctuations in blood calcium level after the medicine is given once a day. 
Za boljše razumevanje posledic izrazitega nihanja ravni kalcija v krvi po dajanju zdravila enkrat dnevno bodo potrebni nadaljnji podatki.
Natpar contains the active substance parathyroid hormone. 
Zdravilo Natpar vsebuje zdravilno učinkovino paratiroidni hormon.
Natpar is injected under the skin of the thigh using the Natpar pen. 
Zdravilo Natpar se s peresnikom Natpar injicira pod kožo stegna.
Then carry on as usual the next day. 
Nato nadaljujte kot običajno naslednji dan.
These measures will help protect the environment 
Takšni ukrepi pomagajo varovati okolje.
90% Confidence Interval 
90-% interval zaupanja
Elderly population (> 65 years) 
Starejša populacija (> 65 let)
There are only very few data available on patients with African origin. 
Na voljo je zelo malo podatkov za bolnike afriškega izvora.
% of Patients with Response 
% bolnikov z odgovorom
Infusion Volume 1 and Time 2 
Volumen infuzije 1 in čas 2